- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05483322
An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
An Open-Label, Expanded Access Protocol of LAM-002A (Apilimod Dimeyslate Capsules), Administered to a Single Subject With C9ORF72-Associated Frontotemporal Dementia (FTD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Expanded Access Type
- Individual Patients
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of C9ORF72-associated FTD with documentation of a clinical genetic test demonstrating the presence of a pathogenic repeat expansion in C9ORF72
- Age 18 or older
- Capable of providing informed consent at the Screening Visit and complying with study procedures throughout the study, in the Principal Investigator's opinion.
- In the case that the subject lacks the ability to provide informed consent. Informed consent will be sought from the subject's surrogate representative.
- Able to safely swallow study drug capsule at screening and throughout study. May use thickened substances to assist in swallowing drug.
Exclusion Criteria:
Clinically significant unstable medical condition (other than FTD) that would pose a risk to the subject, according to the Principal Investigator's judgment (e.g., cardiovascular instability, systemic infection, or clinically significant laboratory abnormality or ECG changes).
Gastrointestinal disease (e.g., gastric or intestinal bypass surgery, jejunostomy tube, pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory bowel disease, chronic diarrheal illness, bowel obstruction) that might interfere with drug absorption or with interpretation of gastrointestinal AEs.
Gastrostomy tube placement is allowed prophylactically or to supplement nutrition/hydration but may not be used for study drug administration.
- Hepatic profile showing any of the following:
i. Serum alanine aminotransferase (ALT) >5 × upper limit of normal (ULN). ii. Serum aspartate aminotransferase (AST) >5 × ULN. iii. Serum bilirubin >1.5 × ULN. c. Renal profile showing an estimated creatinine clearance (eClCR) <30 mL/minute (with eClCR to be calculated by the method at the laboratory performing the serum creatinine test).
- Presence of a neurodegenerative cognitive or motor syndrome (e.g., Alzheimer's disease, Parkinson's disease) not related to the C9ORF72 repeat expansion.
- Presence of unstable psychiatric disease or substance abuse that would impair ability of the participant to provide informed consent, in the Principal Investigator's opinion.
- Active cancer or history of cancer, except for the following: basal cell carcinoma or successfully treated squamous cell carcinoma of the skin, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies curatively treated and with no evidence of disease recurrence for at least 3 years. Active cancer includes cancers with current disease manifestations or therapy that could adversely affect subject safety and longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.
- Prior solid organ transplantation.
- Ongoing immunosuppressive therapy including systemic or enteric corticosteroids at screening or for the duration of the trial, at the discretion of the site investigator and medical monitor.
- Use within 14 days prior to randomization or for the duration of the trial of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4 or expected requirement for chronic use of a strong inhibitor or inducer of CYP3A4 during study therapy (see Table 2 for a l list of drugs known to be strong inhibitors or inducers of CYP3A4), at the discretion of the Principal Investigator or Sponsor.
- Use within 14 days prior to randomization or for the duration of the trial of drug that is a moderate-to-strong substrate of CYP2C9 (including warfarin, tolbutamide, phenytoin, glimepiride) or expected requirement for chronic use of such drugs during study therapy, at the discretion of the Principal Investigator or Sponsor.
- Use of investigational treatments for FTD (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the Screening Visit.
- Exposure at any time to any gene therapies under investigation for the treatment of FTD (off-label use or investigational).
- If female, breastfeeding, known to be pregnant, planning to become pregnant during the study, or of child-bearing potential and unwilling to use effective contraception for the duration of the trial and for ≥30 days after discontinuing treatment.
- Anything that would place the subject at increased risk or preclude the subject's full compliance with or completion of the study, in the Principal Investigator's opinion.
- If the subject is being re-screened, the disqualifying condition has not been resolved, or the mandatory wash-out duration has not occurred.
Study Plan
How is the study designed?
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Language Disorders
- Communication Disorders
- Speech Disorders
- Frontotemporal Lobar Degeneration
- Aphasia
- Dementia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
Other Study ID Numbers
- LAM-002A-FTD-EAP
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Frontotemporal Dementia
-
University of California, San FranciscoForest LaboratoriesCompletedSemantic Dementia | Frontal Lobe Dementia | Frontotemporal Lobe DementiaUnited States
-
Mayo ClinicRecruitingPrimary Progressive Aphasia | Behavioral Variant of Frontotemporal Dementia | Frontotemporal Dementia, Behavioral VariantUnited States
-
University of PennsylvaniaEnrolling by invitationFrontotemporal Degeneration | Frontotemporal Dementia | Frontotemporal Dementia, Behavioral Variant | FTDUnited States
-
Columbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedTauopathies | Frontotemporal Dementia (FTD) | Frontotemporal Lobar Degeneration (FTLD)United States
-
Massachusetts General HospitalNational Institutes of Health (NIH); National Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Caregiver Stress Syndrome | Caregiver Burnout | Dementia, Mild | Dementia Moderate | Dementia Severe | Dementia FrontotemporalUnited States
-
Lawson Health Research InstituteRecruitingLewy Body Dementia (LBD) | Alzheimer Dementia (AD) | Dementia, FrontotemporalCanada
-
BiogenCompletedFrontotemporal Dementia | Behavioral Variant Frontotemporal DementiaUnited States
-
Vesper Biotechnologies ApSRecruitingDementia, FrontotemporalNetherlands
-
HealthPartners InstituteTerminatedFrontotemporal Dementia, Behavioral VariantUnited States
-
Mayo ClinicNational Institute of Neurological Disorders and Stroke (NINDS); National Institute...CompletedFamilial Frontotemporal DementiaUnited States, Canada
Clinical Trials on LAM-002A
-
AI Therapeutics, Inc.Active, not recruitingAmyotrophic Lateral Sclerosis | ALSUnited States
-
University of Cape TownUniversity of Zimbabwe; University of Zambia; NIMR - Mbeya Medical Research ProgrammeCompletedTuberculosisZambia, Zimbabwe, South Africa, Tanzania
-
Mansoura UniversityCompletedTB - Tuberculosis HIV
-
AI Therapeutics, Inc.CompletedLymphoma, Non-Hodgkin; Leukemia, Chronic LymphocyticUnited States
-
dr. Stefano NavaRecruitingSleep Apnea Syndromes | Sleep Disorder | Lymphangioleiomyomatosis | Hypopnea SyndromeItaly
-
AI Therapeutics, Inc.CompletedAcute Myeloid Leukemia | OncologyUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Jerry A. Nick, M.D.Enrolling by invitationCystic FibrosisUnited States
-
Shanghai Public Health Clinical CenterUnknownHIV Infections | Tuberculosis | Non-Tuberculous Mycobacterial Pneumonia
-
University of Southern DenmarkOdense University Hospital; University of Ghana; Odense Patient Data Explorative... and other collaboratorsCompletedAcquired Immunodeficiency Syndrome | Tuberculosis, Pulmonary | Human Immunodeficiency Virus (HIV) | Extrapulmonary TuberculosisGhana